Oral JAK inhibitor baricitinib effective in JIA

被引：0
|
作者：
McHugh, Jessica
机构：
[1] Nature Reviews Rheumatology,
来源：
NATURE REVIEWS RHEUMATOLOGY | 2023年 / 19卷 / 09期
关键词：
D O I：
10.1038/s41584-023-01019-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
引用
收藏
页码：539 / 539
页数：1
相关论文
共 50 条
  • [31] A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
    Murakami, Kohei
    Kobayashi, Yasuhiro
    Uehara, Shunsuke
    Suzuki, Takako
    Koide, Masanori
    Yamashita, Teruhito
    Nakamura, Midori
    Takahashi, Naoyuki
    Kato, Hiroyuki
    Udagawa, Nobuyuki
    Nakamura, Yukio
    PLOS ONE, 2017, 12 (07):
  • [32] THE JAK INHIBITOR (BARICITINIB) INHIBITS IFNΓ-INDUCED GLIOSTATIN EXPRESSION IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES
    Joyo, Yuji
    Waguri-Nagaya, Yuko
    Kawaguchi, Yohei
    Oguri, Yusuke
    Nozaki, Masahiro
    Asai, Kiyofumi
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1497 - 1497
  • [33] A Case of Anti-TNFα Therapies Induced Lupus Panniculitis Successfully Improved With a JAK Inhibitor (Baricitinib)
    Grechin, Cristina
    Doheny, Jane
    Pilson, Keith
    Howard, Donough
    Roche, Muireann
    JEADV CLINICAL PRACTICE, 2025,
  • [34] Alleviation of isolated nail lichen planus by the JAK1/2 inhibitor Baricitinib: a case report
    He, Juan
    Weng, Tengyu
    Zhu, Wenwei
    Yang, Yi
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [35] Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib
    Kuley, Runa
    Duvvuri, Bhargavi
    Hasnain, Sabeeha
    Dow, Ernst R.
    Koch, Alisa E.
    Higgs, Richard E.
    Krishnan, Venkatesh
    Lood, Christian
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [36] Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
    Radi, Giulia
    Simonetti, Oriana
    Rizzetto, Giulio
    Diotallevi, Federico
    Molinelli, Elisa
    Offidani, Annamaria
    HEALTHCARE, 2021, 9 (11)
  • [37] JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
    Hou, Zhanying
    Su, Xuehan
    Han, Guangming
    Xue, Ruzeng
    Chen, Yangxia
    Chen, Ye
    Wang, Huan
    Yang, Bin
    Liang, Yunsheng
    Ji, Suyun
    FRONTIERS IN MEDICINE, 2022, 9
  • [38] Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study
    Dougados, Maxime
    van der Heijde, Desiree
    Chen, Ying-Chou
    Greenwald, Maria
    Drescher, Edit
    Liu, Jiajun
    Beattie, Scott
    de la Torre, Inmaculada
    Rooney, Terence
    Schlichting, Douglas
    De Bono, Stephanie
    Emery, Paul
    Bookman, Arthur
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1188 - 1188
  • [39] 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Taylor, Peter
    Genovese, Mark
    Keystone, Edward C.
    Drescher, Edit
    Berclaz, Pierre-Yves
    Lee, Chin
    Fidelus-Gort, Rosalind
    Schlichting, Douglas
    Beattie, Scott
    Luchi, Monica
    Macias, William
    RHEUMATOLOGY, 2013, 52 : 44 - 45
  • [40] BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CDMARD THERAPY: RESULTS OF THE PHASE 3 RA-BUILD STUDY
    Dougados, M.
    van der Heijde, D.
    Chen, Y. -C.
    Greenwald, M.
    Drescher, E.
    Liu, J.
    Beattie, S.
    de la Torre, I.
    Rooney, T.
    Schlichting, D.
    de Bono, S.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 79 - 79
12345